Efficacy of Combined Aromatase Inhibitor and Luteinizing Hormone- Releasing Hormone Agonist in Premenopausal Metastatic Breast Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Endocrine therapy is the preferred treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC). We investigated the efficacy of combined aromatase inhibitor (AI) and luteinizing hormone-releasing hormone (LHRH) agonist in premenopausal patients with HR-positive MBC. Methods: We retrospectively analyzed the medical records of 21 HR-positive premenopausal MBC patients treated with combined AI and LHRH agonist therapy. Results: The median follow-up period was 32.9 months. The overall response rate was 47.6%, with three complete responses (14.3%) and seven partial responses (33.3%). Nine patients (42.9%) achieved stable disease lasting more than 6 months; thus, the clinical benefit rate was 90.4%. The median time to progression was 45.4 months. No patients experienced grade 3 or 4 toxicity. Conclusion: Combined AI and LHRH agonist treatment safely and effectively induced remission or prolonged disease stabilization, suggesting that this could be a promising treatment option for HR-positive premenopausal patients with MBC.
Abstract
Purpose: Endocrine therapy is the preferred treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC). We investigated the efficacy of combined aromatase inhibitor (AI) and luteinizing hormone-releasing hormone (LHRH) agonist in premenopausal patients with HR-positive MBC. Methods: We retrospectively analyzed the medical records of 21 HR-positive premenopausal MBC patients treated with combined AI and LHRH agonist therapy. Results: The median follow-up period was 32.9 months. The overall response rate was 47.6%, with three complete responses (14.3%) and seven partial responses (33.3%). Nine patients (42.9%) achieved stable disease lasting more than 6 months; thus, the clinical benefit rate was 90.4%. The median time to progression was 45.4 months. No patients experienced grade 3 or 4 toxicity. Conclusion: Combined AI and LHRH agonist treatment safely and effectively induced remission or prolonged disease stabilization, suggesting that this could be a promising treatment option for HR-positive premenopausal patients with MBC.
참고문헌 (20)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), "Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials", Lancet, 365, pp.1687~1717 (2005)
- Gennari A, "Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies", Cancer, 104, pp.1742~1750 (2005)
- Stockler M, "Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer", Cancer Treat Rev, 26, pp.151~168 (2000)
- Osoba D, "Health-related quality of life as a treatment endpoint in metastatic breast cancer", Can J Oncol, 5(Suppl 1), pp.47~53 (1995)
- Geels P, "Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer", J Clin Oncol, 18, pp.2395~2405 (2000)
- Beatson GT, "On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases", Trans Med Chir Soc Edinb, 15, pp.153~179 (1896)
- Gradishar WJ, "Breast cancer version 3.2014", J Natl Compr Canc Netw, 12, pp.542~590 (2014)
- Dowsett M, "The biology of steroid hormones and endocrine treatment of breast cancer", Breast, 14, pp.452~457 (2005)
- Giordano SH, "NCCN guidelines updates breast cancer", J Natl Compr Canc Netw, 16(5S), pp.605~610 (2018)
- Pagani O, "Adjuvant exemestane with ovarian suppression in premenopausal breast cancer", N Engl J Med, 371, pp.107~118 (2014)
- Forward DP, "Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer", Br J Cancer, 90, pp.590~594 (2004)
- Cheung KL, "Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women", Eur J Cancer, 46, pp.2936~2942 (2010)
- Carlson RW, "Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women", J Clin Oncol, 28, pp.3917~3921 (2010)
- Yao S, "Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer", Endocr J, 58, pp.509~516 (2011)
- Nishimura R, "Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial", Oncol Rep, 29, pp.1707~1713 (2013)
- Tanaka K, "Luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer", Surg Today, 44, pp.1678~1684 (2014)
- Park IH, "Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy", J Clin Oncol, 28, pp.2705~2711 (2010)
- Michaud LB, "Combination endocrine therapy in the management of breast cancer", Oncologist, 6, pp.538~546 (2001)
- Ma CX, "Predicting endocrine therapy responsiveness in breast cancer", Oncology (Williston Park), 23, pp.133~142 (2009)